Endo International Plc - Company Profile
Powered by
All the data and insights you need on Endo International Plc in one report.
- Save hours of research time and resources with
our up-to-date Endo International Plc Strategy Report
- Understand Endo International Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures, and commercializes various branded pharmaceuticals, generic pharmaceuticals, sterile injectables and other products through its operating companies. It sells generic products in the US in various categories including urology, pain management, orthopedics, endocrinology, central nervous system (CNS) disorders, cancer, cardiovascular diseases, and women’s health. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrine disorders, and pain management. Endo also provides over the counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.
Endo International Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Generic Pharmaceuticals: | Lidoderm |
Pain Management | Opanaer |
Urology | Testopel |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Product Recall | In April, Par Pharmaceutical, Inc. expanded its recall of Treprostinil Injection 20mg/20mL (1mg/mL) due to potential silicone particulate presence. |
2024 | Product Recall | In March, Par Pharmaceutical, Inc. recalled one lot of Treprostinil Injection 20mg/20mL (1mg/mL) for the presence of silicone particulates in the product solution. |
2024 | New Products/Services | In March, Par Pharmaceutical, Inc., introduced Ibuprofen-famotidine 800 mg/26.6 mg tablets. |
Competitor Comparison
Key Parameters | Endo International Plc | AbbVie Inc | Takeda Pharmaceutical Co Ltd | Teva Pharmaceutical Industries Ltd | Viatris Inc |
---|---|---|---|---|---|
Headquarters | Ireland | United States of America | Japan | Israel | United States of America |
City | Dublin | North Chicago | Chuo-Ku | Tel Aviv | Canonsburg |
State/Province | - | Illinois | Tokyo | Tel Aviv | Pennsylvania |
No. of Employees | 2,931 | 50,000 | 49,095 | 35,001 | 38,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Mark G. Barberio | Chairman; Director | Executive Board | 2021 | - |
Blaise Coleman | President; Director; Chief Executive Officer | Executive Board | 2020 | 49 |
Mark Bradley | Executive Vice President; Chief Financial Officer | Senior Management | 2020 | 54 |
Cheryl Stouch | Chief Information Officer; Senior Vice President - Information Technology | Senior Management | 2022 | - |
Susan Williamson | Chief Compliance Officer; Senior Vice President | Senior Management | 2018 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer